within Pharmacolibrary.Drugs.ATC.D;

model D07XC03
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0002,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.2,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D07XC03</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Mometasone is a synthetic corticosteroid used topically for its anti-inflammatory, antipruritic, and vasoconstrictive properties. It is commonly used in the treatment of dermatological conditions such as eczema, psoriasis, and allergic dermatitis. Mometasone is also available as a nasal spray for allergic rhinitis and as an inhaler for asthma. It is approved and widely used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for topical mometasone furoate in healthy adult subjects based on available literature and standard reference data.</p><h4>References</h4><ol><li><p>Spada, F, Barnes, TM, &amp; Greive, KA (2018). Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids. <i>The Australasian journal of dermatology</i> 59(3) e168–e174. DOI:<a href=&quot;https://doi.org/10.1111/ajd.12762&quot;>10.1111/ajd.12762</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29411351/&quot;>https://pubmed.ncbi.nlm.nih.gov/29411351</a></p></li><li><p>Crim, C, Pierre, LN, &amp; Daley-Yates, PT (2001). A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. <i>Clinical therapeutics</i> 23(9) 1339–1354. DOI:<a href=&quot;https://doi.org/10.1016/s0149-2918(01)80113-2&quot;>10.1016/s0149-2918(01)80113-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11589253/&quot;>https://pubmed.ncbi.nlm.nih.gov/11589253</a></p></li><li><p>Kaur, N, Sharma, K, &amp; Bedi, N (2018). Topical Nanostructured Lipid Carrier Based Hydrogel of Mometasone Furoate for the Treatment of Psoriasis. <i>Pharmaceutical nanotechnology</i> 6(2) 133–143. DOI:<a href=&quot;https://doi.org/10.2174/2211738506666180523112513&quot;>10.2174/2211738506666180523112513</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29788899/&quot;>https://pubmed.ncbi.nlm.nih.gov/29788899</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D07XC03;
